Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02889796 · ClinicalTrials.gov registry record · Phase 3
Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
A Phase 3 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,759
- Enrollment target
NCT02889796 is a Phase 3 study that has completed, run by Gilead Sciences. The registered enrollment target is 1,759 participants.
The verdict
NCT02889796, a Phase 3 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,759 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the effects of filgotinib versus placebo for the treatment of signs and symptoms of rheumatoid arthritis (RA) as measured by the percentage of participants achieving an American College of Rheumatology 20% improvement response (ACR20) at Week 12.
Interventions
- DRUG Adalimumab
- DRUG Filgotinib
- DRUG MTX
- DRUG Placebo to match filgotinib
- DRUG Placebo to match adalimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,759 participants |
| Start Date | 2016-08-30 |
| Est. Completion | 2019-06-20 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02889796
The ClinicalTrials.gov registry entry for NCT02889796 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,759 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Adalimumab is the first listed.
NCT02889796 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02889796 about?
NCT02889796 is a clinical study titled "Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate". The primary objective of this study is to evaluate the effects of filgotinib versus placebo for the treatment of signs and symptoms of rheumatoid arthritis (RA) as measured by the percentage of participants achieving an American College of Rheumatology 20% improvement response (ACR20) at Week 12.
What is the current status of trial NCT02889796?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,759 participants. The study started on 2016-08-30. Estimated completion is 2019-06-20.
What interventions are being tested in trial NCT02889796?
The interventions under investigation include: Adalimumab (DRUG), Filgotinib (DRUG), MTX (DRUG), Placebo to match filgotinib (DRUG), Placebo to match adalimumab (DRUG).
Who is sponsoring clinical trial NCT02889796?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.